Printer Friendly

ROGER W. BRIMBLECOMBE, Ph.D., JOINS VERTEX BOARD OF DIRECTORS

 CAMBRIDGE, Mass., March 11 /PRNewswire/ -- Roger W. Brimblecombe, Ph.D., has been added to the Board of Directors of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). In commenting on the appointment, Joshua Boger, the Company's president and chief executive officer said, "We are pleased to announce the addition of Dr. Brimblecombe to our Board of Directors. Brimblecombe has had a distinguished career in the pharmaceutical industry and has impressive scientific credentials. He will be a significant contributor to Vertex's growth and development as our structure-based drug design programs move from discovery into development and commercialization."
 Brimblecombe had a successful seventeen-year career at Smith Kline & French, where he held the position of Vice President of Research and Development for Europe and Japan. He is currently Chairman of Vanguard Medica Ltd., a developer of pharmaceutical products, and a director of other biopharmaceutical companies in the United States and the United Kingdom.
 He was chairman of the Scientific Committee of the Association of the British Pharmaceutical Industry on two occasions, is past president of the Comparative Medicine Section of the Royal Society of Medicine, and Fellow of the Royal College of Pathologists. Brimblecombe has authored three books and over one hundred papers in his field. A pharmacologist by training, he holds Doctor of Philosophy and Doctor of Science degrees from the University of Bristol, England.
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery which uses atomic level information to design synthetic compounds that interact with protein targets involved in disease processes. Vertex is using advanced techniques of biology, chemistry and biophysics to create novel, small molecule compounds that the Company plans to develop as orally deliverable drugs to treat major human diseases. Vertex is concentrating on the development of drugs in the areas of immunology, inflammation and antiviral therapy.
 -0- 3/11/93
 /CONTACT: Contact: Stephanie K. Marrus, Director, Corporate Communications, 617-499-2490, or Robert Gottlieb, Senior Vice President, Feinstein Partners Inc., 617-577-8110, for Vertex/
 (VRTX)


CO: Vertex Pharmaceuticals ST: Massachusetts IN: MTC SU: PER

TM -- NE001 -- 4949 03/11/93 07:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 11, 1993
Words:348
Previous Article:GREENVILLE CHOSEN AS SITE FOR CHICK-FIL-A'S FIRST DRIVE-THRU-ONLY RESTAURANT IN THE NATION
Next Article:AWT NAMES ARTHUR L. GLENN PRESIDENT AND CHIEF OPERATING OFFICER
Topics:


Related Articles
HECTOR J. GOMEZ, M.D., PH.D., JOINS VERTEX AS VP MEDICAL AFFAIRS
VICKI SATO TO HEAD RESEARCH AT VERTEX PHARMACEUTICALS
ROBERT SCHOOLEY, M.D., JOINS VERTEX SCIENTIFIC ADVISORY BOARD
DONALD R. CONKLIN AND BARRY M. BLOOM NAMED TO VERTEX BOARD OF DIRECTORS
CREATIVE BIOMOLECULES, INC. APPOINTS VICE PRESIDENT, CORPORATE DEVELOPMENT
VICKI L. SATO, PH.D., PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND DEVELOPMENT AT VERTEX PHARMACEUTICALS
DR. STEPHEN C. HARRISON JOINS VERTEX'S SCIENTIFIC ADVISORY BOARD
DR. EUGENE CORDES JOINS VERTEX'S SCIENTIFIC ADVISORY BOARD
Dr. Joshua Boger Named Vertex Pharmaceuticals' Chairman of the Board of Directors
Vertex Pharmaceuticals Appoints Andrew S. Marks as Patent Counsel

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters